A Randomized, Open Label Phase 1 Study in Healthy Participants to Evaluate the Relative Bioavailability of a Single Dose of Various Test Solid Formulations of TAK-020 Compared With a Single Dose of Reference Oral Solution and to Evaluate the Food Effect and Potentially the Dose Proportionality of the Optimal Solid Dose Formulation
Phase of Trial: Phase I
Latest Information Update: 27 Oct 2016
At a glance
- Drugs TAK 020 (Primary) ; TAK 020
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Takeda
- 07 Sep 2016 Status changed from recruiting to completed.
- 01 Jun 2016 Status changed from not yet recruiting to recruiting.
- 01 Apr 2016 New trial record